-transparent.png){kind=logo}
Acitretin, the active metabolite of etretinate, has the clinical advantage of a much shorter terminal elimination half-life. We report the results of a double-blind, placebo-controlled trial of acitretin (Soriatane) in 15 patients with moderate to severe psoriasis. Patients received 25 mg or 50 mg daily of acitretin or placebo in a double-blind fashion for 8 weeks and then were given 25 to 75 mg acitretin daily during an open study. Only two placebo patients completed the double-blind phase; one patient's psoriasis worsened, and one showed no significant change. All 15 patients then completed at least 8 weeks with 25 to 75 mg acitretin daily, with a moderate change in erythema, scaling, and induration (mean 28% to 37% improvement) but with minimal change in the percentage of body surface area involved. Prolonged treatment (greater than or equal to 20 weeks) with acitretin resulted in further significant improvement and a 44% reduction of involved surface area from baseline.
E A Olsen, and
W W Weed, and
C J Meyer, and
L M Cobo
February 1988,
Lancet (London, England),
E A Olsen, and
W W Weed, and
C J Meyer, and
L M Cobo
January 2023,
Complementary medicine research,
E A Olsen, and
W W Weed, and
C J Meyer, and
L M Cobo
October 1989,
The British journal of dermatology,
E A Olsen, and
W W Weed, and
C J Meyer, and
L M Cobo
March 1991,
Journal of the American Academy of Dermatology,
E A Olsen, and
W W Weed, and
C J Meyer, and
L M Cobo
June 2006,
The British journal of dermatology,
E A Olsen, and
W W Weed, and
C J Meyer, and
L M Cobo
January 1989,
Acta dermato-venereologica. Supplementum,
E A Olsen, and
W W Weed, and
C J Meyer, and
L M Cobo
July 2002,
Neurology,
E A Olsen, and
W W Weed, and
C J Meyer, and
L M Cobo
February 1995,
The American journal of psychiatry,
E A Olsen, and
W W Weed, and
C J Meyer, and
L M Cobo
July 1998,
The American journal of psychiatry,
E A Olsen, and
W W Weed, and
C J Meyer, and
L M Cobo
April 2017,
European journal of dermatology : EJD,
